T-DM1 reduces long-term risk of death in HER2-positive breast cancer patients
In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...
Le Lézard11h
BioVaxys Developing DPX to be the Carrier of Choice for mRNA Vaccines, a market projected to grow to USD$48,000,000,000 by 2030*
BioVaxys Technology Corp. (FRA: 5LB) ("BioVaxys" or the "Company") highlights the potential for its DPXtm non-systemic immune educating platform to address the inherent limitations of lipid ...
Two ‘off-label’ chemo drugs successfully used together in Singapore to fight bladder cancer
They were used on five patients, and four of them are now either in remission or cancer-free. Read more at straitstimes.com.
The EMBO Journal5h
Gut microbiota interact with breast cancer therapeutics to modulate efficacy
The gut microbiome, or the community of microorganisms residing in the gastrointestinal tract, has emerged as an important ...
securities9h
Niobium Phosphide Could Make Data Centers More Efficient By Addressing Material Weaklink
New Conductor Needed For Nanochips When producing advanced computer chips, the main technological focus has been on reducing ...